Botulinum Toxin Type B: Where Do We Stand?

Publisher： Karger

E-ISSN： 1421-9913|46|3|113-114

ISSN： 0014-3022

Source： European Neurology, Vol.46, Iss.3, 2001-10, pp. : 113-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Challenges of RSV Vaccines. Where do we Stand?

Recent Patents on Anti-Infective Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 99-108

Bentham Science Publishers

Access to resources Recommend Favorite

Imaging Subclinical Atherosclerosis: Where Do We Stand?

Current Cardiology Reviews, Vol. 13, Iss. 1, 2016-11 ,pp. : 47-55

Bentham Science Publishers

Access to resources Recommend Favorite

Omega 3: Where Do We Stand?

By Versari Daniele Daghini Elena Salvetti Guido Salvetti Antonio

High Blood Pressure & Cardiovascular Prevention, Vol. 15, Iss. 4, 2008-01 ,pp. : 225-230

Adis International

Access to resources Recommend Favorite

4 years after withdrawal of rofecoxib: where do we stand today?

By Jaksch W.

Rheumatology International, Vol. 28, Iss. 12, 2008-10 ,pp. : 1187-1195

Springer Publishing Company

Access to resources Recommend Favorite

Gastric Electrical Stimulation in Gastroparesis: Where Do We Stand?

Digestive Diseases, Vol. 24, Iss. 3-4, 2006-07 ,pp. : 260-266

Karger

Access to resources Recommend Favorite